Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Atazanavir-ritonavir on Lumefantrine PK in HIV Patients
NCT04531072Phase 4Completed
- Sponsor
- Fogarty International Center
- Start
- Sep 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of atazanavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fogarty International Center. Primary endpoints: Area under the curve of lumefantrine at 2 weeks, Maximum plasma concentration of lumefantrine at 2 weeks and 6 more. Started Sep 2018; status: completed.
02
Drugs
atazanavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04531072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531072.